Unlike other death receptors, the expression of DR5 is much lower in normal tissues than in cancerous tissues [36,39], implying that targeting DR5 might induce cancer-specific cell death and cause few adverse effects in normal cells. The gene discussed is TNFRSF10B; the disease is cancer.